Close this search box.


Jun 22 2022

Replenishing the malaria drug discovery pipeline


Replenishing the malaria drug discovery pipeline; introduction of a new drug discovery workflow using a nanoluciferase malaria parasite

Malaria is a deadly disease, that affected over 240 million people in 2020, an increase over progress in previous years. Despite advances in malariology, the challenge of finding the right drugs to treat the illness is complex.
During this hourlong webinar, drug discovery experts Dr James Duffy (Medicines for Malaria Ventures (MMV)), Dr Koen Dechering (TropIQ) and Martijn Timmerman (Pivot Park Screening Center (PPSC)) will share:

  • perspectives and strategies in antimalaria drug discovery
  • the biology of the malaria models
  • small molecule tactics and technical assay development
  • a novel transgenic malaria reporter strain with excellent performance in high-throughput screening
  • screening and hit generation of active compounds against the blood stage of the Plasmodium falciparum parasite
  • triage of large compound libraries screening

Watch this webinar on 22 June 16.00 hrs. (CET)

 Register here.

Part 1: perspective on antimalarials and overall strategy
James Duffy will open the webinar by explaining that, despite advances in our understanding of the underlying molecular basis of malaria and there being several new combination therapies in clinical development, new, affordable and safe malaria medicines are urgently required to:

  • overcome increasing resistance against artemisinin-based combination treatments to treat vulnerable populations
  • interrupt the parasite life cycle by blocking transmission to the vectors
  • prevent infection and target parasite species that remain dormant in the liver

part 2: Introduction to biology of malaria models
Koen Dechering will introduce a novel reporter parasite that was generated by integration of a nanoluciferase expression cassette into the parasite’s genome and demonstrate the reporter’s sensitivity and reproducibility in high throughput screening formats.
Furthermore, he will:

  • discuss pros and cons of phenotypic versus target-based screening
  • the life cycle of the malaria parasite and discuss the challenges in malaria drug discovery

Part 3: Small molecule tactics and technical assay development on malaria models
Martijn Timmerman will discuss:

  • miniaturization and optimization of a 1536-well screening assay to screen the blood-stage of P. falciparum
  • the importance of triaging after the screening of a 140,000-compound library

Part 4: Hit prioritization discussion
Lastly, James Duffy will present a new screening and selection cascade for hit generation of compounds active against the blood-stage of P. falciparum.




Other Organizers

Pivot Park


All Day

Hourly Schedule


12:00 - 13:00

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?


The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.